Combat Medical reports 68% high-grade recurrence-free survival at 12 months in BCG-unresponsive non-muscle invasive bladder cancer study

By News Medical November 9, 2026 #BCGunresponsive, #Bladder, #Cancer, #combat, #Data, #Health, #highgrade, #invasive, #Medical, #medicine, #Months, #nonmuscle, #recurrencefree, #reports, #Study, #survival

Combat Medical (Combat), a medical device company optimising the delivery and efficacy of cancer therapeutics, today announced new real-world data showing 68% high-grade recurrence-free survival (HG-RFS) at 12 months in patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) after hyperthermic intravesical chemotherapy (HIVEC®) with mitomycin C.